Navigation Links
Edwards Lifesciences Completes Sale of LifeStent Product Line to Bard
Date:1/14/2008

IRVINE, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, announced today that it has completed the sale of certain assets related to the Edwards LifeStent product line to C.R. Bard, consistent with the terms previously reported.

About Edwards Lifesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
3. Spectranetics to Present at The A.G Edwards Growth Conference on September 18
4. Edwards Plan on AIDS Unveiled Today
5. AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy
6. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
7. Elizabeth Edwards to Join SEIU Activists at Conference
8. Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007
9. Edwards Lifesciences Announces Schedule of Activities at TCT 2007
10. Edwards Lifesciences to Present at the Southern California Investor Conference
11. Eligard(R) six-month formulation successfully completes European approval procedure
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:REES Announces New Baltimore Office 2Health News:Buffalo Personal Injury Lawyers Cellino & Barnes Donate $1M to UB School of Law, Appear on Cover of School's Philanthropy Magazine 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Patriot Scientific Corporation Announces New Director 2
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Landauer Acquires Global Physics Solutions Inc as Platform to Expand Into Medical Physics Services Market 6108 1Landauer Acquires Global Physics Solutions Inc as Platform to Expand Into Medical Physics Services Market 6108 2Landauer Acquires Global Physics Solutions Inc as Platform to Expand Into Medical Physics Services Market 6108 3Landauer Acquires Global Physics Solutions Inc as Platform to Expand Into Medical Physics Services Market 6108 4Landauer Acquires Global Physics Solutions Inc as Platform to Expand Into Medical Physics Services Market 6108 5Keryx Biopharmaceuticals Inc Announces Third Quarter 2009 Financial Results 6104 1Keryx Biopharmaceuticals Inc Announces Third Quarter 2009 Financial Results 6104 2Keryx Biopharmaceuticals Inc Announces Third Quarter 2009 Financial Results 6104 3Keryx Biopharmaceuticals Inc Announces Third Quarter 2009 Financial Results 6104 4Keryx Biopharmaceuticals Inc Announces Third Quarter 2009 Financial Results 6104 5Keryx Biopharmaceuticals Inc Announces Third Quarter 2009 Financial Results 6104 6Breast Cancer Drugs May Fight Cervical Cancer Too 61020 1Breast Cancer Drugs May Fight Cervical Cancer Too 61020 2